Survival and tumor characteristics of German hereditary breast cancer patients
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Reports from different countries have been inconclusive in attempting to relate the BRCA1 mutation status to the survival of breast cancer patients. The purpose of this study was to investigate overall and disease-free survival for German hereditary breast cancer patients. Data on clinical outcome and data on age at diagnosis of breast cancer, histology, tumor size, lymph node status, histological grade, and laterality of 36 breast cancer patients from 12 families with a BRCA1 mutation and from one family with strong evidence for linkage to BRCA1 were compared with those of 49 hereditary breast cancer patients from 23 families that did not harbor a BRCA1 mutation. Overall and disease-free survival was estimated for both groups. BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04). Also, BRCA1-associated tumors more frequently were of larger size (p = 0.041) and higher grade of malignancy (p = 0.005) than non-BRCA1-associated tumors. Whereas no difference in overall survival was seen, disease-free survival at 10 years differed significantly with 53.3% for BRCA1 mutation carriers and 76% for non-carriers (p = 0.02). However, after stratification for age and in multivariate analysis for mutation status, age, and bilaterality, it was shown that the worse prognosis for BRCA1 mutation carriers disappeared. Our results suggest that the worse prognosis of BRCA1 mutation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297 · cited 1×
“For statistical analysis, mutation carriers were compared to non-carriers using univariate survival analysis using the Kaplan-Meier estimator and multivariate survival analysis using the proportional hazard model [ 27 ].”
MethodA Strong Candidate for the Breast and Ovarian Cancer Susceptibility Gene BRCA1
Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., et al. (1994) · Science · doi:10.1126/science.7545954 · Cited by 6,071 · cited 1×
“In the context of high-risk families, one important gene is the BRCA1 gene on chromosome 17q21 [ 3 ].”
BackgroundGenetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Self-citationLinkage of Early-Onset Familial Breast Cancer to Chromosome 17q21
Hall, J. M., Lee, M. K., Newman, B., Morrow, J. E., Anderson, L. A., Huey, B., & King, M.-C. (1990) · Science · doi:10.1126/science.2270482 · Cited by 2,550 · cited 1×
“Our study also supported the reported earlier age of diagnosis of women harboring a BRCA1 mutation [ 7 , 9]. Breast cancers in younger patients generally have adverse prognostic factors [29, 30] and were found to have a worse prognosis, especially in patients under 40 years of age [31, 32].”
ResultRisks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Burke, W. (1997) · JAMA · doi:10.1001/jama.277.12.997 · Cited by 955
Unusual case of Smith‐Lemli‐Opitz syndrome “type II”
Seller, M. J., Russell, J., & Tint, G. S. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320560305 · Cited by 585
Stratton, M. R. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10109-4 · Cited by 579
Research works printed but not linked: 1
- Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland: Krebs in Deutschland. Häufigkeiten und Trends. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland (Hrsg), Saarbücken, 1997
Cited by
Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
Foulkes, W. D. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg050 · Cited by 970
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Robson, M. E., Chappuis, P. O., Satagopan, J., Wong, N., Boyd, J., Goffin, J. R., Hudis, C., Roberge, D., Norton, L., Bégin, L. R., et al. (2003) · Breast Cancer Research · doi:10.1186/bcr658 · Cited by 307
“Several reports suggested that women with germline mutations in BRCA1 are more likely to die from their disease than are women with sporadic breast cancer [3–6].”
BackgroundThe Genetic Epidemiology of Breast Cancer Genes
Thompson, D., & Easton, D. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048770.90334.3b · Cited by 257
Zhong, Q., Peng, H.-L., Zhao, X., Zhang, L., & Hwang, W.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1816 · Cited by 203
“Second, because of the variety of endpoints reported in breast cancer studies, we operationally defined breast cancer PFS to include MFS or DDFS for studies that did not provide DFS and had to exclude LRFS and CRFS results (which were considered to be parts of PFS for some studies) from a few studies.”
InfluentialGenetic susceptibility for breast cancer: How many more genes to be found?
Oldenburg, R. A., Meijers-Heijboer, H. E. J., Cornelisse, C. J., & Devilee, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.004 · Cited by 170
“Other studies have uggested that BRCA1 tumors are larger and more often ssociated with axillary lymph node involvement [217–219], t a s g ming a non-parametric model, and lod: lod-score under heterogeneity.”
BackgroundSurvival and prognostic factors in BRCA1-associated breast cancer
Brekelmans, C. T. M., Seynaeve, C., Menke-Pluymers, M., Brüggenwirth, H. T., Tilanus‐Linthorst, M. M. A., Bartels, C. C. M., Kriege, M., van Geel, A. N., Crépin, C., Blom, J., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj095 · Cited by 137
Prognosis of BRCA-associated breast cancer: a summary of evidence
Bordeleau, L., Panchal, S., & Goodwin, P. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0566-z · Cited by 135
van den Broek, A. J., Schmidt, M. K., Veer, L. V. ‘., Tollenaar, R. A. �. �., & van Leeuwen, F. E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120189 · Cited by 146
Robson, M. E., Boyd, J. A., Borgen, P. I., & Cody, H. S. (2001) · Current Problems in Surgery · doi:10.1016/s0011-3840(01)70035-4 · Cited by 136
Chappuis, P. O., Kapusta, L., Bégin, L. R., Wong, N., Brunet, J.-S., Narod, S. A., Slingerland, J., & Foulkes, W. D. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4045 · Cited by 119
BRCA1 : mechanisms of inactivation and implications for management of patients
Kennedy, R. D., Quinn, J. E., Johnston, P. G., & Harkin, D. P. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11087-7 · Cited by 123
Lee, E.-H., Park, S.-K., Park, B., Kim, S., Lee, M. H., Ahn, S., Son, B., Yoo, K., & Kang, D. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0859-2 · Cited by 107
“2000 3.80 1.30‐11.0 0.71 f Hamann a,c [ 13 ] 2000 1.22 0.65‐2.28 0.34 g”
BackgroundResultInfluentialGoffin, J. R., Chappuis, P. O., Bégin, L. R., Wong, N., Brunet, J., Hamel, N., Paradis, A., Boyd, J., & Foulkes, W. D. (2003) · Cancer · doi:10.1002/cncr.11080 · Cited by 110
van den Broek, A. J., van ’t Veer, L. J., Hooning, M. J., Cornelissen, S., Broeks, A., Rutgers, E. J., Smit, V. T. H. B. M., Cornelisse, C. J., van Beek, M., Janssen-Heijnen, M. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3942 · Cited by 104
The role of BRCA mutation testing in determining breast cancer therapy
Trainer, A. H., Lewis, C. R., Tucker, K., Meiser, B., Friedlander, M. L., & Ward, R. L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.175 · Cited by 104
BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis
Zhu, Y., Wu, J., Zhang, C., Sun, S., Zhang, J., Liu, W., Huang, J., & Zhang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12158 · Cited by 103
Molina‐Montes, E., Perez-Nevot, B., Pollán, M., Sánchez‐Cantalejo, E., Espín, J., & Sánchez, M. (2014) · The Breast · doi:10.1016/j.breast.2014.10.005 · Cited by 99
“patients with younger age at breast cancer diagnosis and with clinical phenotypes that are more commonly related to BRCA mutations are those who usually undergo DNA testing) some studies excluded the index cases in sensitivity analyses so as to minimize these biases and to confirm the lifetime risk of CBC in affected…”
Backgroundvan Roosmalen, M. S., Verhoef, L. C. G., Stalmeier, P. F. M., Hoogerbrugge, N., & van Daal, W. A. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.035 · Cited by 91
BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling
Nicoletto, M. O., Donach, M. E., Nicolo, A. D., Artioli, G., Banna, G. L., & Monfardini, S. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0233 · Cited by 83
Germline Genetic Variation, Cancer Outcome, and Pharmacogenetics
Coate, L. E., Cuffe, S. D., Horgan, A. M., Hung, R. J., Christiani, D. C., & Liu, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2336 · Cited by 78
Eerola, H., Vahteristo, P., Sarantaus, L., Kyyr�nen, P., Pyrh�nen, S., Blomqvist, C., Pukkala, E., Nevanlinna, H., & Sankila, R. (2001) · International Journal of Cancer · doi:10.1002/ijc.1341 · Cited by 65
Deng, M., Chen, H., Zhu, X., Luo, M., Zhang, K., Xu, C., Hu, K., Cheng, P., Zhou, J., Zheng, S. S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32184 · Cited by 65
“However, in multivariate analysis, the worse prognosis for BRCA1 mutation carriers disappeared.(15,46) In contrast, some other studies have reported that DFS was similar for patients with P<0.”
ResultQuenneville, L. A., Phillips, K., Ozcelik, H., Parkes, R. K., Knight, J. A., Goodwin, P. J., Andrulis, I. L., & O'Malley, F. P. (2002) · Cancer · doi:10.1002/cncr.10949 · Cited by 58
Templeton, A. J., Gonzalez, L. D., Vera-Badillo, F., Tibau, A., Goldstein, R., Šeruga, B., Srikanthan, A., Pandiella, A., Amir, E., & Ocaña, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154789 · Cited by 53
Bonadona, V., Dussart, S., Voirin, N., Sinilnikova, O. M., Mignotte, H., Mathevet, P., Bremond, A. G., Treilleux, I., Martin, A., Romestaing, P., et al. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9288-7 · Cited by 52
“Some reports have failed to confirm this trend [20–24] (Table 1) and, as discussed by several authors [31–33], many of these studies which were not conducted in an outbred population, are subject to potential selection biases, particularly toward survival, i.”
ResultBRCA1/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma
Jin, T. Y., Park, K. S., Nam, S. E., Yoo, Y. B., Park, W. S., & Yun, I. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073754 · Cited by 41
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., van den Ouweland, A., van Geel, B., Brekelmans, C. T. M., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9781-7 · Cited by 40
“However, studies investigating overall survival in BRCA1-associated versus age-matched sporadic BC patients have reported contradictive results, with some studies describing a worse survival, and others an equal survival for BRCA1-associated BC patients [2, 5–10].”
ResultTilanus‐Linthorst, M. M. A., Bartels, K. C. M., Alves, C., Bakri, B., Crepin, E., van den Ouweland, A., Klijn, J. G. M., Meijers-Heijboer, H. E. J., & Brekelmans, C. T. M. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9054-2 · Cited by 23
“had no sporadic control group (Table 4) [9,16,17,20].”
BackgroundAre BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Evans, D. G., & Howell, A. (2003) · Breast Cancer Research · doi:10.1186/bcr748 · Cited by 23
“These studies were still subject to bias as individuals were either ascertained through existing proven BRCA1 families (the necessity again for a living affected individual) [5,6,7] or some time after diagnosis in Jewish families [8].”
BackgroundSu, L., Xu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T., Lin, B., & Xie, Y. (2020) · International Journal of Cancer · doi:10.1002/ijc.32918 · Cited by 25
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer
Hubert, A., Mali, B., Hamburger, T., Rottenberg, Y., Uziely, B., Peretz, T., & Kadouri, L. (2008) · Familial Cancer · doi:10.1007/s10689-008-9223-7 · Cited by 17
“Older studies have shown improved survival [1], however, subsequent studies in BRCA1 carriers demonstrated equal [ 2 , 3] or worse survival [4–6].”
ResultTreatment of Hereditary Breast Cancer
Robson, M. E. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.07.011 · Cited by 17
Foulkes, W. D., Rosenblatt, J. M., & Chappuis, P. O. (2001) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1014791115760 · Cited by 17
“These more recent studies are characterized by a larger number of cases studied with a longer follow-up, and five of them showed a significantly worse survival for BRCA1 or BRCA2 mutation carriers(42,48,50,51,53).”
ResultContribution of BRCA2 germline mutations to hereditary breast/ovarian cancer in Germany
Hamann, U., Liu, X., Lange, S., Ulmer, H. U., Benner, A., & Scott, R. J. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.e12 · Cited by 14
Self-citationInfluence of a family history of breast and/or ovarian cancer on breast cancer outcomes
Cao, A., He, M., Di, G., WU, J., Lu, J.-S., Liu, G., SHEN, Z.-Z., & Shao, Z. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.275 · Cited by 12
“Several studies have reported that individuals with a family history of BOC are more likely to present with smaller tumors and a higher grade of malignancy than those without a family history (9), while others studies have failed to find these associations (10,11).”
BackgroundJacobi, C. E., Nagelkerke, N. J. D., van Houwelingen, H. C., & de Bock, G. H. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0223 · Cited by 14
“The reviews provided 20 articles (63-82) and the second search provided five articles, of which only one was not yet identified through the reviews (83).”
BackgroundCabaret, A.-S., Lévêque, J., Dugast, C., Blanchot, J., & Grall, J. Y. (2003) · Gynécologie Obstétrique & Fertilité · doi:10.1016/s1297-9589(03)00058-4 · Cited by 7
Molecular Pathology of Breast Cancer
Gru, A. A., & Allred, D. C. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4900-3_6 · Cited by 7
Lynch, H. T., Marcus, J. N., Lynch, J. A., Snyder, C., & Rubinstein, W. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00021-8 · Cited by 5
Intronic TP53 Germline Sequence Variants Modify the Risk in German Breast/Ovarian Cancer Families
Liu, X., Sinn, H., Ulmer, H., Scott, R. J., & Hamann, U. (2004) · Hereditary Cancer in Clinical Practice · doi:10.1186/1897-4287-2-3-139 · Cited by 4
“In Germany, germline mutations in BRCA1 and BRCA2 account for about 30% of hereditary breast/ovarian cancer families [19-23].”
BackgroundSelf-citationChoi, D. H., Jin, S. Y., Lee, D. W., Kim, E. S., & Kim, Y. H. (2008) · Radiation Oncology Journal · doi:10.3857/jkstro.2008.26.1.65 · Cited by 1
Genetic Predisposition to Male and Female Breast Cancer
Syrjäkoski, K. (2004) · Tampere University Institutional Repository (Tampere University) · Cited by 1
Breast Cancer Families in Finland
Eerola, H. (2001) · Työväentutkimus Vuosikirja
Molecular Genetics of Breast Cancer
Gilbert, M. B., Schleicher, M., Würtz, S. Ø., Hoheisel, J. D., Hoff, C., Poustka, A., Frenzel, H., Brauch, H. B., Brüning, T., Ko, Y., et al. (2001)
Susceptibility genes in hereditary breast cancer
Vahteristo, P. (2003) · Helda - University of Helsinki Institutional Repository
Hamad, G., Ali, S., & Jubrael, J. (2016) · Journal of Zankoy Sulaimani - Part A · doi:10.17656/jzs.10556
Port, E. R., & Cody, H. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5221-0.00081-4
Distinct Tumor Subtypes and Contralateral Breast Cancer Risk in BRCA1 and BRCA2 Carriers
Sun, J., Liu, H., Li, D., Yao, L., Chen, J., Hu, L., Zhang, J., Xu, Y., & Xie, Y. (2026) · Current Oncology · doi:10.3390/curroncol33110678
Metadata
- Authors
- Hamann, U., & Sinn, H.-P.
- Affiliations
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Venue
- Breast Cancer Research and Treatment
- Published
- 2000-01
- Volume
- 59
- Issue
- 2
- Pages
- 185-192
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2078493457
- Semantic Scholar
- 5dafca3b3ff9d49bd3a1d2cfb00d36ecd01349a6
- Cited by
- 48
- References
- 42
- Citations by year
- 2022: 1 · 2020: 1 · 2019: 1 · 2016: 3 · 2015: 2 · 2014: 2 · 2012: 1
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
- Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
- Keywords
- hereditary breast cancer, BRCA1 mutation, disease-free survival, overall survival, age at diagnosis, contralateral breast cancer, tumor size, histological grade, prognostic factors, German patients
- MeSH terms
- Adult, Breast Neoplasms, DNA Mutational Analysis, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Survival Analysis, Point Mutation, Age of Onset, Genes, BRCA1, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.